Introduction
Diabetic nephropathy (DN) is one of the most common complications of diabetes mellitus (DM) which leads to end-stage renal failure in 30%-40% of DM patients. [1] [2] [3] The incidence of DN will rapidly increase with increase in the incidence of DM in China in the decades to come. 4, 5 Oxidative stress injury and TGF-β/Smads signal transduction are vital to the development and progression of DN. The supererogatory advanced glycation end products (AGEs) and ROS act as pivotal mediators of microvascular injury when Du et al induced by DM and trigger various cell signaling pathways involved in the development of DN. Oxidative stress injury caused by ROS and AGEs can actuate TGF-β/Smads signaling which is involved in the development of fibrosis in renal tubular epithelial cells. 6, 7 Many results have shown that TGF-β expression is upregulated in animal renal fibrosis models as well as human counterparts. 8, 9 The transition of renal tubular epithelial cells to myofibroblasts which synthesize excessive amounts of extracellular matrix thus leading to renal fibrosis is modulated by TGF-β through TGF-β/Smads signaling pathway. 2 Furthermore, oxidative stress and TGF-β/Smads signaling together with other disease processes interactively and rapidly promote DN. Therefore, agents with anti-oxidative or TGF-β1/Smads signaling prohibitive competence are likely to possess a therapeutic effect on DN.
Ginsenoside Rg1 is one of the main active ingredients of Panax ginseng C.A. Mey. Its proportion is the main criterion which determines the quality of P. ginseng. 10 Studies have reported that Ginsenoside Rg1 has a strong anti-oxidative and anti-fibrotic effect. [11] [12] [13] [14] Astragaloside IV, a characteristic and active constituent of Radix Astragali, possesses many biological effects. 15 Many studies have shown that Astragaloside IV has an excellent renal protective effect. 16 Only a specific amount of P. ginseng and Radix Astragali and other frequently prescribed traditional Chinese medicines such as Shenqi Jiangtang Granules should be applied to avoid complications in DM patients. Some evidences show that a mixture of herbal medicines has a better effect than a single medicine in clinical practice. In this study, we aimed to determine whether the combination of Ginsenoside Rg1 and Astragaloside IV has a therapeutic effect on DN and its underlying mechanism.
Materials and methods chemicals
Ginsenoside Rg1 (purity 98%) and Astragaloside IV (purity 98%) were purchased from ChengDu ConBon Biotech Co., Ltd. (Chengdu, China). The methane dicarboxylic aldehyde (MDA), catalase (CAT), glutathione peroxidase (GSH-PX) and total anti-oxidative capacity (T-AOC) assay kits for rats were bought from Jiancheng Bioengineering Institute (Nanjing, China). Rat blood urea nitrogen (BUN), serum creatinine (SCr), β 2 -microglobulin (β 2 -MG) and urinary creatinine (UCr) ELISA kits were also purchased from Jiancheng Bioengineering Institute. Streptozotocin (STZ) was bought from Sigma (St Louis, MO, USA 
animals
A total of 50 male adult Wistar rats (180-220 g) were purchased from Laboratory Animal Center of Jilin University. All the experiments were approved by the Animal Care Committee of Jilin University Pharmaceutical College (in accordance with the Animal Experimental Ethical guidelines of Jilin University; permit number: 2017050802). The rats were kept at a temperature of 22°C±2°C on a 12-hour light/dark cycle and fed on a normal laboratory diet and water ad libitum.
in vivo experiments
The rats were marked after acclimating to the facilities for 7 days. Then, eight rats were randomly chosen and designated as N group, and the rest were intraperitoneally administered 60 mg/kg of STZ with 0.1 mol/L sodium citrate solution (pH 4.50). [17] [18] [19] The blood glucose levels of all the rats, except N group, were measured at 72 hours after STZ injection (first experimental day). Only the rats with a blood glucose concentration higher than 13.8 mmol/L were chosen as model rats and used further in our study.
Model rats were randomly divided into four groups (n=8): M group, G group, A group and C group. Rats in N group and M group were intragastrically (ig) administered vehicle daily, rats in G group were ig administered 50 mg/kg/day of Ginsenoside Rg1, rats in A group were ig administered 
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combination of rg1 and astragaloside iV reduces Os and TgF-β1/smads 16 mg/kg/day of Astragaloside IV and rats in C group were ig administered 50 mg/kg/day of Ginsenoside Rg1 and 16 mg/ kg/day of Astragaloside IV on the first experimental day.
Detection of the levels of MDa, caT, gsh-PX, T-aOc, BUn, scr, β 2 -Mg and Ucr
At the end of 8 weeks (56th experimental day), the rats were housed in individual metabolic cages (ZS Dichuang Co., Ltd., Shanghai, China) to collect 24-hour urine samples. The plasma samples were used to detect MDA, CAT, GSH-PX, T-AOC, BUN and SCr levels, while urine samples were used to measure β 2 -MG and UCr levels using assay kits according to the manufacturer's instructions.
immunohistochemical staining and assessment in each group
After euthanization (57th experimental day), the kidneys (left) were harvested and rinsed free from blood with PBS. After fixing in 10% neutral formalin and embedding in paraffin, the antigen of kidney tissue slides was exposed by treatment with boiling citrate buffer (0.01 mol/L, pH 6.0). Then, the slides were respectively incubated with TGF-β1, Smad2/3, Smad7 and CTGF antibodies for immunohistochemical analysis and examined using a light microscope (Nikon Ti). The analyses were performed to test for the gray value of the immunohistochemical stainings using Motic Images Advanced 3.2.
real-time Pcr analysis in rats' kidney tissue
The kidneys (right) were harvested and kept in liquid nitrogen for real-time PCR analysis. Total RNA was extracted from rats' kidney tissue and reverse transcribed to cDNA according to the manufacturer's protocol. Then, real-time PCR was proceeded with SYBR™ Select Master Mix, and expression was detected using iCycler iQ (Bio-Rad). ACTB was employed as the internal standard in our study. The ratio of TGF-β1, Smad7 and CTGF was normalized with ACTB. We took each factor of N group as 1.0000 to calculate and compare the homologous factors in the other groups.
statistical analysis
Statistical analyses were performed utilizing SPSS 20.0 program. Results were expressed as mean ± SD and analyzed using one-way ANOVA and post hoc least square difference test. Statistical significance was determined at P0.05.
Results

combination of ginsenoside rg1 and astragaloside iV increases Dn rats' anti-oxidative capacity
The results of oxidative stress levels in each group are shown in Figure 1 . STZ injection obviously increased MDA level, but decreased the levels of CAT, GSH-PX and T-AOC as compared with N group (P0.05). As shown in Figure 1A , G group and C group had lower level of MDA (P0.05 vs M group). The rats in C group had the lowest MDA level, although there was no significant difference between G group and C group. G group, A group and C group showed apparent increase in CAT level (P0.05 vs M group; Figure 1B) . Compared with G group, A group had lower CAT level (P0.05) while C group had higher CAT level (P0.05).
The treatment of G group and C group inhibited GSH-PX level decline in plasma (P0.05 vs M group; Figure 1C ). Compared with G group, C group had better GSH-PX level (P0.05 vs G group). In Figure 1D , we could find that rats in G group, A group and C group had improved T-AOC after STZ injection (P0.05 vs M group). The rats in C group had better T-AOC than the other two groups.
combination of ginsenoside rg1 and astragaloside iV improves Dn rats' renal function
The tests showed that STZ injection induced significant increase in the levels of BUN, SCr, β 2 -MG and UCr as compared with N group (P0.05; Figure 2 ). We also found that G group, A group and C group treatments significantly decreased the levels of BUN, SCr, β 2 -MG and UCr (P0.05 vs M group; Figure 2) .
Compared with G group and A group, rats in C group had lower BUN levels (P0.05 vs G group and P0.05 vs A group; Figure 2A ). As shown in Figure 2B , C group had the lowest level of SCr among the three groups (P0.05 vs G group and P0.05 vs A group). The rats in G group had lower SCr level than rats in A group (P0.05). As shown in Figure 2C , we found that C group had lower β 2 -MG level than the other two groups (P0.05 vs G group and P0.05 vs A group). However, there was no significant difference between G group and A group. As shown in Figure 2D , C group had the lowest UCr level after 8 weeks of treatment (P0.05 vs G group or A group). However, there was no significant difference between G group and A group (P0.05).
combination of ginsenoside rg1 and astragaloside iV inhibits TgF-β1/smads signaling cascade In order to explore the effect of combination of Ginsenoside Rg1 and Astragaloside IV on TGF-β1/Smads signaling in DN rats' kidneys, immunohistochemical staining and realtime PCR were performed. Compared with N group, rats in M group showed severe immunopositivity for TGF-β1, Smad2/3 and CTGF, but no immunopositivity for Smad7. However, G group, A group and C group treatments diminished immunopositivity for TGF-β1, Smad2/3 and CTGF and elevated immunopositivity for Smad7 (Figure 3 ). More importantly, C group had the lowest levels of TGF-β1, Smad2/3 and CTGF and the highest level of Smad7 among the three groups as revealed by the gray value of immunohistochemical stainings tested using Motic Images Advanced 3.2 ( Figure 4) .
Real-time PCR analysis showed that STZ injection induced overexpression of TGF-β1 (P0.05) and CTGF (P0.05), but decreased the expression of Smad7 (P0.05) as compared with N group. The results demonstrated that G group, A group and C group had attenuated expression of TGF-β1 and CTGF but increased expression of Smad7 (P0.05 vs M group). In addition, C group showed better effect than the other two groups ( Figure 5 ).
Discussion
Hyperglycemic microenvironment, which leads to tubulointerstitial fibrosis and glomerulosclerosis, induces structural and functional abnormalities in the kidney at a very early stage of DM. 20, 21 Tubulointerstitial injury actually occurs earlier than glomerular injury in the development of DN. 16, 22 Oxidative stress injury and overactivation of TGF-β1/ Smads signaling are the major culprits in DN. [23] [24] [25] [26] There is some causal link between oxidative stress and TGF-β1/ Smads signal transduction in the development and progression of DN. As we know, renal cells exhibit enhanced glucose 
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Du et al uptake in DM, but some cell populations such as glomerular mesangial cells cannot decrease glucose transport rates efficiently to maintain intracellular glucose homeostasis. 27 As a result, cytosol and mitochondria in these cells will produce more ROS beyond local antioxidant capacity. Oxidative stress induced by the redundant ROS in renal cells such as podocytes and mesangial cells induces the development and progression of DN. 28 AGEs are the other momentous cell metabolic products produced in DM patients. Oxidative stress may hasten AGEs formation. 29 Superfluous ROS are also produced along with AGEs, inducing ROS/AGEs self-perpetuating cycle in DM. 24 Since most AGEs are cleared by the kidneys, they are likely to accumulate and interact with renal cells. Studies have shown that AGEs correlate with the expression of TGF-β1 and CTGF. 30 TGF-β is a polypeptide with three isoforms in mammals namely TGF-β1, TGF-β2 and TGF-β3. The isoforms share the same conserved regions in structure and signaling pathway, but differ in distribution. TGF-β1 is expressed in all kinds of renal cells, while TGF-β2 is expressed in cells of nervous system and TGF-β3 is expressed in rhabdomyosarcoma cells. 31 Many experiments have found that the transition of Ψ P0.05 vs a group. The severer the immunopositivity was, the lower the gray value tested.
Figure 5
The ratio of TgF-β1, smad7 and cTgF mrna expression in each group. 
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combination of rg1 and astragaloside iV reduces Os and TgF-β1/smads tubular epithelial cells to myofibroblasts leading to renal fibrosis is modulated by TGF-β1/Smads signaling. 32, 33 In addition, CTGF, one of the main downstream products of TGF-β1/Smad signaling pathway, contributes to renal fibrosis and exerts positive feedback on the signaling. Smad7 as a negative factor can downregulate TGF-β1/Smads signal transduction. Hence, anti-oxidative stress and inhibition of TGF-β1/Smads signaling cascade may be vital targets for drugs used to treat DN.
P. ginseng and Radix Astragali are together compatible with other herbs used in traditional Chinese medicine for clinical treatment of diabetes. Ginsenoside Rg1 and Astragaloside IV are the two main bioactive components present in P. ginseng and Radix Astragali, respectively. Many experimental studies have indicated that both Ginsenoside Rg1 and Astragaloside IV exhibit some anti-oxidative ability and suppressive activity on TGF-β1/Smads signaling, [34] [35] [36] [37] [38] [39] [40] but the application of combination of Ginsenoside Rg1 and Astragaloside IV and its benefits in DN have not been reported.
In our study, we found that the treatment groups (G group, A group and C group) showed different levels of improvement in DN. We found that rats in C group (treated with the combination of Ginsenoside Rg1 and Astragaloside IV) had the lowest MDA level but the highest CAT, GSH-PX and T-AOC levels among the three treatment groups. In addition, G group had lower MDA level but higher CAT, GSH-PX and T-AOC levels than A group. We can conclude that Ginsenoside Rg1 (50 mg/kg/day) has better anti-oxidative stress ability than Astragaloside IV (16 mg/kg/day). However, Astragaloside IV can strengthen the anti-oxidative stress effect of Ginsenoside Rg1 in DN. The rats in C group had better renal function than G group or A group rats with lower levels of BUN, SCr, β 2 -MG and UCr. There was almost no difference between G group and A group (merely in SCr, P0.05). We may conclude that Ginsenoside Rg1 and Astragaloside IV interact with each other to improve renal function in DN. The inhibiting effect of the three treatments on TGF-β1/Smads signaling was detected in our experiments. G group, A group and C group treatments all significantly decreased both factor and mRNA overexpression of TGF-β1 and CTGF but increased Smad7 expression in the kidneys of DN rats. We also conclude that Ginsenoside Rg1 has a better inhibiting effect on TGF-β1 overexpression, while Astragaloside IV has a better activating effect on Smad7 expression. Thus, combination of Ginsenoside Rg1 and Astragaloside IV may exert excellent inhibiting effect on TGF-β1/Smads signaling cascade.
Conclusion
Our findings provide some evidence for the protective effect of the combination of Ginsenoside Rg1 and Astragaloside IV on DN rats. We conclude that combination of Ginsenoside Rg1 and Astragaloside IV can benefit DN patients by attenuating oxidative stress, improving renal function and inhibiting TGF-β1/Smads signaling cascade. Therefore, our study provides laboratory evidence for the beneficial effect of the combination of Ginsenoside Rg1 and Astragaloside IV on the treatment of DN. However, more investigations are required to study the underlying mechanism in detail.
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